DK1404377T3 - Forbedrede chelatorkonjugater - Google Patents

Forbedrede chelatorkonjugater

Info

Publication number
DK1404377T3
DK1404377T3 DK02745600T DK02745600T DK1404377T3 DK 1404377 T3 DK1404377 T3 DK 1404377T3 DK 02745600 T DK02745600 T DK 02745600T DK 02745600 T DK02745600 T DK 02745600T DK 1404377 T3 DK1404377 T3 DK 1404377T3
Authority
DK
Denmark
Prior art keywords
chelator conjugates
improved
improved chelator
radiometal
conjugates
Prior art date
Application number
DK02745600T
Other languages
English (en)
Inventor
Torgrim Engell
Colin Mill Archer
Harry John Wadsworth
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of DK1404377T3 publication Critical patent/DK1404377T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
DK02745600T 2001-07-10 2002-07-10 Forbedrede chelatorkonjugater DK1404377T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0116815.2A GB0116815D0 (en) 2001-07-10 2001-07-10 Improved chelator conjugates

Publications (1)

Publication Number Publication Date
DK1404377T3 true DK1404377T3 (da) 2006-01-30

Family

ID=9918227

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02745600T DK1404377T3 (da) 2001-07-10 2002-07-10 Forbedrede chelatorkonjugater

Country Status (20)

Country Link
US (2) US7597875B2 (da)
EP (1) EP1404377B1 (da)
JP (1) JP5015409B2 (da)
KR (1) KR100892009B1 (da)
CN (4) CN101537190A (da)
AT (1) ATE304866T1 (da)
AU (1) AU2002317317B2 (da)
BR (1) BR0210965A (da)
CA (1) CA2450690C (da)
DE (1) DE60206272T2 (da)
DK (1) DK1404377T3 (da)
ES (1) ES2250671T3 (da)
GB (1) GB0116815D0 (da)
HU (1) HU228850B1 (da)
IL (1) IL159388A0 (da)
MX (1) MXPA04000210A (da)
NO (1) NO334093B1 (da)
RU (1) RU2298012C2 (da)
WO (1) WO2003006070A2 (da)
ZA (1) ZA200400143B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379885A4 (en) * 2001-01-05 2005-07-06 Univ Duke CONTRAST REINFORCING AGENT FOR MAGNETIC RESONANCE IMAGING
HU230901B1 (hu) * 2001-07-10 2019-01-28 Ge Healthcare Limited Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
NO20030115D0 (no) * 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
US7431914B2 (en) 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
US7763234B2 (en) * 2004-03-04 2010-07-27 Ge Healthcare As Pharmaceutical compounds
JP5116480B2 (ja) * 2004-11-22 2013-01-09 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
ES2380680T3 (es) * 2005-06-08 2012-05-17 Ge Healthcare Limited Procedimiento de uso de monóxido de carbono [11C] en la síntesis de marcaje interno de ésteres marcados con 11C mediante carbonilación fotoinducida de radicales libres sensitizados
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
US8124806B2 (en) 2006-02-15 2012-02-28 Ge Healthcare As Contrast agents
US7943117B2 (en) * 2006-06-08 2011-05-17 Atomic Energy Council—Institute of Nuclear Research Method for testing radiochemical purity of Tc-99m-TRODAT-1
JP2010512310A (ja) * 2006-12-11 2010-04-22 ジーイー・ヘルスケア・アクスイェ・セルスカプ 放射性標識ペプチド系化合物及びその使用
CN102300866B (zh) 2008-12-02 2015-08-26 墨尔本大学 作为放射性药物的含氮大环共轭物
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
ES2804509T3 (es) * 2010-07-27 2021-02-08 Serac Healthcare Ltd Composiciones radiofarmacéuticas
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201110767D0 (en) 2011-06-24 2011-08-10 Ge Healthcare Ltd Infection imaging
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
CN105377287A (zh) * 2013-02-15 2016-03-02 托马斯杰弗逊大学 用于肿瘤成像的试剂盒
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3131585B1 (en) 2014-03-19 2020-07-15 Universität Zürich Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
WO2019217571A1 (en) * 2018-05-08 2019-11-14 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
CN112105393A (zh) 2018-05-16 2020-12-18 爱默蕾大学 苯乙烯基苯并噻唑衍生物及在成像中的用途
CN111548275A (zh) * 2020-05-27 2020-08-18 龙曦宁(上海)医药科技有限公司 一种2-(氨基甲基)-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588978A (en) * 1977-07-19 1981-05-07 Ici Ltd Coating processes
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5808091A (en) * 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
JP3083157B2 (ja) * 1993-08-04 2000-09-04 アマーシャム・インターナショナル・ピーエルシー 酸素欠乏性組織に局在する放射性金属錯体
CA2156605A1 (en) * 1994-01-12 1995-07-20 Bracco International B.V. Ligands and metal complexes thereof
CA2179990A1 (en) * 1994-01-12 1995-07-20 Gary Robert Bower Biological targeting agents
HUP0102154A3 (en) * 1998-05-15 2009-01-28 Ge Healthcare Ltd Labelled glutamine and lysine analogues
US6783711B2 (en) * 2000-05-23 2004-08-31 Ge Osmonics, Inc. Process for preparing a sulfonamide polymer matrix
JP4009198B2 (ja) 2001-03-08 2007-11-14 松下電器産業株式会社 インクジェット記録用インク、該インクの製造方法、並びに該インクを備えたインクカートリッジ及び記録装置

Also Published As

Publication number Publication date
US8852550B2 (en) 2014-10-07
NO334093B1 (no) 2013-12-09
CN101537190A (zh) 2009-09-23
CN101607913A (zh) 2009-12-23
NO20035597L (no) 2004-03-03
IL159388A0 (en) 2004-06-01
WO2003006070A3 (en) 2003-08-21
JP5015409B2 (ja) 2012-08-29
MXPA04000210A (es) 2004-07-23
EP1404377A2 (en) 2004-04-07
JP2005500325A (ja) 2005-01-06
BR0210965A (pt) 2004-06-08
US7597875B2 (en) 2009-10-06
CN101607913B (zh) 2012-07-04
ZA200400143B (en) 2004-12-29
EP1404377B1 (en) 2005-09-21
GB0116815D0 (en) 2001-08-29
US20040258619A1 (en) 2004-12-23
US20100040542A1 (en) 2010-02-18
HUP0401265A2 (hu) 2004-09-28
KR100892009B1 (ko) 2009-04-07
DE60206272D1 (de) 2005-10-27
NO20035597D0 (no) 2003-12-16
RU2003137592A (ru) 2005-05-20
RU2298012C2 (ru) 2007-04-27
AU2002317317B2 (en) 2005-11-17
HK1064585A1 (en) 2005-02-04
CN101538313A (zh) 2009-09-23
CN1527727A (zh) 2004-09-08
KR20040017287A (ko) 2004-02-26
HU228850B1 (en) 2013-06-28
WO2003006070A2 (en) 2003-01-23
ATE304866T1 (de) 2005-10-15
DE60206272T2 (de) 2006-07-13
CA2450690C (en) 2009-03-24
HUP0401265A3 (en) 2005-11-28
CA2450690A1 (en) 2003-01-23
ES2250671T3 (es) 2006-04-16
CN100509061C (zh) 2009-07-08

Similar Documents

Publication Publication Date Title
NO20035597D0 (no) Forbedrede chelator-konjugater
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
ECSP034600A (es) Compuestos de lactama
IL181529A (en) A method for radiofluorination, a compound containing radioactive fluorine and its use in the preparation of a radioactive drug
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
BR0307702A (pt) Formulações de solução contendo anticorpo
MA30042B1 (fr) Composes calcilytiques
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
TR200003389T2 (tr) 2-(2-klorofenil)-3,4-dihidro-2H-pirol türevleri.
DE60124296D1 (de) Biphenylcarbonsäureamide, die sich als lipidsenker eignen
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
TR199901017A2 (xx) B�cek ilac� terkibi.
EA200401289A1 (ru) Новые противоинфекционные соединения, способы их получения и фармацевтические композиции, содержащие эти соединения
DE60322562D1 (de) Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
DE60330629D1 (de) Ether von 2,2,4-Trimethylpentane-1,3-Diolen als Duftstoff
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
NO20021429D0 (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
EA200400764A1 (ru) 1,3-диарилпроп-2-ен-1-оны, композиция на их основе и применение
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
BR0212397A (pt) Sìntese de glicosìdeos de solano
ES2183543T3 (es) Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica.
HN1999000157A (es) 1,2,3 tetrahidroquinolinas 2 - sustituidas 4 - amino sustituidas.